191 related articles for article (PubMed ID: 34656107)
1. Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.
Shimokawa M; Hayashi T; Nishimura J; Satoh T; Fukunaga M; Matsui R; Tsuji Y; Mizuki F; Kogawa T
BMC Cancer; 2021 Oct; 21(1):1111. PubMed ID: 34656107
[TBL] [Abstract][Full Text] [Related]
2. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
[TBL] [Abstract][Full Text] [Related]
3. Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Koch S; Wein A; Siebler J; Boxberger F; Neurath MF; Harich HD; Hohenberger W; Dörje F
Support Care Cancer; 2013 Sep; 21(9):2395-402. PubMed ID: 23568765
[TBL] [Abstract][Full Text] [Related]
4. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
[TBL] [Abstract][Full Text] [Related]
5. 5HT
Hayashi T; Shimokawa M; Matsuo K; Nishimura J; Iihara H; Nakano T; Egawa T
Cancer Sci; 2021 Feb; 112(2):744-750. PubMed ID: 33274555
[TBL] [Abstract][Full Text] [Related]
6. [Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case].
Abe T; Hachiro Y; Kunimoto M
Gan To Kagaku Ryoho; 2010 Dec; 37(13):2933-5. PubMed ID: 21160274
[TBL] [Abstract][Full Text] [Related]
7. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
8. Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Bubalo JS; Herrington JD; Takemoto M; Willman P; Edwards MS; Williams C; Fisher A; Palumbo A; Chen E; Blanke C; Lopez CD
Support Care Cancer; 2018 Apr; 26(4):1273-1279. PubMed ID: 29090385
[TBL] [Abstract][Full Text] [Related]
9. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea.
Takemoto H; Nishimura J; Komori T; Kim HM; Ota H; Suzuki R; Ikenaga M; Ikeda M; Yamamoto H; Satoh T; Hata T; Takemasa I; Mizushima T; Doki Y; Mori M;
Int J Clin Oncol; 2017 Feb; 22(1):88-95. PubMed ID: 27465476
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.
Hesketh PJ; Sanz-Altamira P; Bushey J; Hesketh AM
Support Care Cancer; 2012 May; 20(5):1043-7. PubMed ID: 21553313
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy.
Shimokawa M; Hayashi T; Kogawa T; Matsui R; Mizuno M; Kikkawa F; Saeki T; Aiba K; Tamura K
Anticancer Res; 2019 Jan; 39(1):225-230. PubMed ID: 30591462
[TBL] [Abstract][Full Text] [Related]
14. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
15. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy.
Chan A; Low XH; Yap KY
J Manag Care Pharm; 2012 Jun; 18(5):385-94. PubMed ID: 22663171
[TBL] [Abstract][Full Text] [Related]
17. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.
dos Santos LV; Souza FH; Brunetto AT; Sasse AD; da Silveira Nogueira Lima JP
J Natl Cancer Inst; 2012 Sep; 104(17):1280-92. PubMed ID: 22911671
[TBL] [Abstract][Full Text] [Related]
18. Herbal medicine for the prevention of chemotherapy-induced nausea and vomiting in patients with advanced colorectal cancer: A prospective randomized controlled trial.
Wu Z; Fu X; Jing H; Huang W; Li X; Xiao C; Li Z; You F
J Ethnopharmacol; 2024 May; 325():117853. PubMed ID: 38341113
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.
Tsuji Y; Baba H; Takeda K; Kobayashi M; Oki E; Gotoh M; Yoshida K; Shimokawa M; Kakeji Y; Aiba K
Expert Opin Pharmacother; 2017 Jun; 18(8):753-758. PubMed ID: 28395603
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies.
Cabanillas Stanchi KM; Ebinger M; Hartmann U; Queudeville M; Feucht J; Ost M; Koch MS; Malaval C; Mezger M; Schober S; Weber S; Michaelis S; Lange V; Lang P; Handgretinger R; Döring M
Drug Des Devel Ther; 2019; 13():3439-3451. PubMed ID: 31686784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
